ONCOS Stock Overview
A biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Oncopeptides AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 11.13 |
| 52 Week High | SEK 42.51 |
| 52 Week Low | SEK 11.01 |
| Beta | -0.61 |
| 11 Month Change | 0% |
| 3 Month Change | -1.59% |
| 1 Year Change | n/a |
| 33 Year Change | -91.38% |
| 5 Year Change | n/a |
| Change since IPO | -91.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONCOS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.5% | -0.9% |
| 1Y | n/a | -25.0% | 6.3% |
Return vs Industry: Insufficient data to determine how ONCOS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how ONCOS performed against the UK Market.
Price Volatility
| ONCOS volatility | |
|---|---|
| ONCOS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 11.1% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ONCOS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ONCOS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 59 | Monica Shaw | www.oncopeptides.com/sv |
Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Oncopeptides AB (publ) Fundamentals Summary
| ONCOS fundamental statistics | |
|---|---|
| Market cap | SEK 942.15m |
| Earnings (TTM) | -SEK 310.39m |
| Revenue (TTM) | SEK 9.48m |
99.4x
P/S Ratio-3.0x
P/E RatioIs ONCOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCOS income statement (TTM) | |
|---|---|
| Revenue | SEK 9.48m |
| Cost of Revenue | SEK 17.00k |
| Gross Profit | SEK 9.46m |
| Other Expenses | SEK 319.85m |
| Earnings | -SEK 310.39m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 10, 2023
| Earnings per share (EPS) | -3.29 |
| Gross Margin | 99.82% |
| Net Profit Margin | -3,274.49% |
| Debt/Equity Ratio | 0% |
How did ONCOS perform over the long term?
See historical performance and comparison